Aquestive Therapeutics, Inc. (AQST) has disclosed a new risk, in the Innovation / R&D category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aquestive Therapeutics, Inc. faces a competitive threat if it lags peers in effectively deploying and governing AI across discovery, development, manufacturing, and commercialization, potentially leading to slower timelines, higher costs, and loss of market share. The company also confronts execution risk, as intense competition for AI talent, data readiness challenges, and the possibility of underperforming AI investments could prevent it from realizing expected productivity gains and margin benefits.
Overall, Wall Street has a Strong Buy consensus rating on AQST stock based on 7 Buys.
To learn more about Aquestive Therapeutics, Inc.’s risk factors, click here.